Rapid Rx Quiz: Semaglutide: The Data So Far

Mary L. Windle, PharmD


September 13, 2023

Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist. It is indicated for type 2 diabetes and chronic weight management. It mimics the GLP-1 hormone that is released in the gastrointestinal tract in response to eating. GLP-1 reduces blood glucose (sugar) by prompting the body to produce more insulin. In higher amounts, GLP-1 also interacts with the parts of the brain that signal a feeling of fullness and reduce appetite. Only three US Food and Drug Administration-approved versions of semaglutide are available, and copycats and compound drugs are cause for concern as they claim to include semaglutide but lack its efficacy and safety. This problem is worsened by supply shortages owing to intense demand.

Are you up on the most recent research into semaglutide that is helping drive patient demand? Test your knowledge with a quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.